The Uttar Pradesh government aims for Rs. 12,000 crore (US$ 1.40 billion) investment in mega pharma park

Uttar Pradesh (UP) is targeting private investment of Rs. 12,000 crore (US$ 1.40 billion) for a mega Bulk Drug Pharma Park in Lalitpur district, located in the Bundelkhand region. The state government plans to invest approximately Rs. 250 crore (US$ 29.18 million) to develop essential infrastructure across the 1,472-acre site. According to Chief Executive Officer (CEO) of the UP State Industrial Development Authority (UPSIDA), Mr. Mayur Maheshwari, this initiative aims to bolster self-reliance in the pharmaceutical sector and position India as the “pharmacy of the world.” The project is expected to generate 14,000 direct and indirect jobs, thereby providing a significant boost to the local economy. India’s pharmaceutical market currently stands at Rs. 5,56,790 crore (US$ 65 billion) and is projected to reach Rs. 10,27,920 crore (US$ 120 billion) by 2030, with UP accounting for roughly 17% of domestic sales. Recently, UPSIDA collaborated with the Confederation of Indian Industry (CII) to organise a conference on ‘Investment Opportunities in UP’s Pharmaceutical Landscape’ in Gujarat to showcase the pharma park to key investors.
In addition, UPSIDA has signed several memoranda of understanding (MoUs) with leading pharmaceutical and healthcare companies, including CSL Lifesciences, Mediheath Diagnostic, Gaman Irradiation, and Obmed Pharma. UP is not only targeting the domestic medical market but is also focusing on expanding into lucrative global exports. Furthermore, the state government has proposed another medical sector project spanning 350 acres under the Yamuna Expressway Industrial Development Authority jurisdiction in Greater Noida, which will house more than 100 medical equipment and device manufacturing units. Mr. Mayur Maheshwari emphasised UP’s emergence as a major industrial hub and reiterated the government’s commitment to supporting investors fully.

Disclaimer: This information has been collected through secondary research and IBEF is not responsible for any errors in the same.